Trial: 202003073

SGN35-31 – A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase

III

Principal Investigator

Bartlett, Nancy

Disease Site

Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov